News | News By Subject | News by Disease News By Date | Search News

Thrombocytopenia News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Geron Corporation (GERN) Tanks As FDA Halts Development Of Blood Disorder Drug     3/13/2014
CytoPharm and Amarillo Biosciences (AMAR) Announce Positive HCV Study Results: Oral Interferon Found to Reverse Thrombocytopenia; Reduced Relapse Rate Seen in Patients With Mild Fibrosis     6/15/2012
Exelixis, Inc. (EXEL) Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients With Hepatocellular Carcinoma     1/23/2012
Amgen (AMGN)'s Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints     12/10/2007
MGI PHARMA, INC. (MOGN) Buys Rights To AkaRx, Inc.'s Blood-Cell Disorder Drug: Upfront Payments of Up to $45 Million     8/29/2007
FDA Approves CSL Behring's Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)     4/2/2007
Baxter Healthcare Corporation (BAX) Assumes Marketing And Distribution Rights For Cangene Corporation's WinRho SDF In The U.S.     3/29/2005
Alexion Pharmaceuticals (ALXN) And XOMA (XOMA) Form Collaboration     12/18/2003
Puget Sound Blood Center Release: Gene That May Provide Link To Bleeding Disorders Discovered     12/2/2003

News from Around the Web

Press Releases
Baxalta (BXLT) Reports Positive Phase 1 Results For BAX 930, Investigational Recombinant ADAMTS13 To Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)     5/25/2016
Xencor Reports Complete Data Results From XmAb7195 Phase 1a Trial Showing Rapid Reduction Of Serum IgE In High IgE Atopic Subjects At American Thoracic Society 2016 International Conference     5/19/2016
Protalex, Inc. (PRTX) Receives Positive Interim Review From Independent Safety Monitoring Committee In Its European Phase Ib Study Of PRTX-100 To Treat Immune Thrombocytopenia     5/2/2016
Amgen (AMGN) Release: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia     4/20/2016
New Patent Issued To Cantex Pharmaceuticals For Its Lead Product Candidate In The Treatment Of Thrombocytopenia And Neutropenia     3/2/2016
Protalex, Inc. (PRTX) Receives Positive Interim Review From Independent Safety Monitoring Committee In Its U.S. Phase I/II Study Of PRTX-100 For Immune Thrombocytopenia     2/29/2016
DelMar Pharma To Present At The Biotech Showcase 2016 On January 12, 2016     1/5/2016
Protalex, Inc. (PRTX) Announces First Patient Dosed In U.S. Phase I/II Study Of PRTX-100 For Immune Thrombocytopenia     11/23/2015
CTI BioPharma Reports Second Quarter 2015 Financial Results     8/7/2015
Rigel (RIGL) Announces Second Quarter 2015 Financial Results     8/5/2015
Positive Results Presented From Proof-Of-Concept Phase 2 Clinical Trial Of Incyte Corporation (INCY)'s Oral JAK1 Inhibitor In Patients With Myelofibrosis     12/10/2013
FDA Approves Bayer HealthCare Pharmaceuticals (BAYA.F)'s New Class of Drug Adempas® (riociguat) Tablets to Treat Adults With PAH and Persistent, Recurrent or Inoperable CTEPH     10/9/2013
Ligand Pharmaceuticals Inc. (LGND) Partner GlaxoSmithKline (GSK) Receives Marketing Authorization From the European Commission (EC) for Additional Revolade™ (Eltrombopag) Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia     9/24/2013
SuppreMol Releases Positive Interim Phase Ib/IIa Results on SM101 in Primary Immune Thrombocytopenia (ITP) Trials     3/15/2012
Neumedicines Inc. Receives Notice of Allowance for Patent Covering Use of HemaMax(TM) (rIL-12) to Treat Chemotherapy-Induced Thrombocytopenia (CIT)     1/31/2011

//-->